Comparison Guide · PRRT

Alpha PRRT vs beta PRRT.

Lu-177 DOTATATE versus Ac-225 DOTATATE for neuroendocrine tumours — physics differences, published response rates, the toxicity trade-off, the salvage role of Ac-225 after Lu-177 progression, and how patient selection actually works.

Dr. Ishita B. Sen, MDDirector & Chief, Nuclear Medicine · FMRI

Published 13 May 2026

Reviewed by Dr. Dharmender Malik

13 min read

Last reviewed by Dr. Dharmender Malik on 13 May 2026 · this article reflects the published primary literature and current clinical practice at FMRI Gurugram.

Introduction

Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumours uses a somatostatin-analogue ligand (typically DOTATATE) labelled with a therapeutic radionuclide. The two clinically meaningful options are Lu-177 (a beta emitter, FDA-approved as Lutathera since 2018) and Ac-225 (an alpha emitter, investigational). This article is a sourced comparison of the two — what the physics actually means, what the published response and toxicity data show, and how the choice between them is made in practice. The simplest framing: Lu-177 is the standard-of-care first-line option with the largest evidence base; Ac-225 is an investigational salvage option for patients who have progressed on Lu-177 and whose disease retains SSTR2 expression.

Physics — what beta versus alpha actually means

AI Overview · short answer

Lu-177 emits beta particles that travel ~2.5 mm in tissue and deposit ~0.2 keV per micrometre (low linear energy transfer, low LET). Ac-225 emits alpha particles that travel only ~50-100 micrometres and deposit ~100 keV per micrometre (high LET, ~500× higher). The alpha emission causes denser DNA damage in a much shorter range — stronger tumour cell killing in small lesions, more pronounced damage to immediately adjacent cells, less crossfire to distant normal tissue^[1]^[2].

The clinical implications:

Bulky tumours — Lu-177 beta range (2.5 mm) provides crossfire that helps reach cells deeper in larger lesions where ligand penetration is limited. Alpha-emitters lose this advantage in bulky disease.
Micrometastatic disease — Ac-225 alpha range (~50-100 µm) precisely matches the size of individual cells and small clusters, theoretically more effective in microscopic disease^[2].
Bone marrow involvement — Lu-177 beta crossfire spreads marrow exposure across a larger volume; Ac-225 short alpha range theoretically spares adjacent marrow more effectively when lesion-targeted^[3].
Resistance pathways — Beta-radiation cell killing is partly via single-strand DNA breaks, which cancer cells can repair more readily over time; alpha radiation produces dense double-strand breaks that are far harder to repair, theoretically overcoming acquired resistance to beta therapy^[4].

Published response data — Lu-177 versus Ac-225 head-to-head

The two foundational evidence sets are the NETTER-1 trial for Lu-177 DOTATATE and the Ballal et al. Indian cohort for Ac-225 DOTATATE. Both are summarised below alongside other published cohort data^[5]^[6]:

Trial / cohort	Radionuclide	n	ORR (RECIST)	DCR	mPFS
NETTER-1 (Strosberg)	Lu-177	116	18%	—	28.4 mo
Brabander (long-term Lu-177)	Lu-177	610	39%	74%	29 mo
Ballal Ac-225 DOTATATE (salvage post-Lu)	Ac-225	32	15.7%	78.1%	not reached
Ballal Ac-225 DOTATATE (treatment-naïve)	Ac-225	91	24%	92.3%	not reached
Yadav Ac-225 DOTATATE	Ac-225	23	50%	87%	—

The two main observations: (1) Lu-177 has the larger, more mature evidence base with established long-term survival data; (2) Ac-225 shows particularly notable response signals in the post-Lu-177 salvage setting — disease control rates of approximately 78 percent in patients who have progressed on Lu-177^[6]. Cross-trial comparison is inherently limited by differences in patient selection, baseline disease characteristics, prior treatment history, and dosing protocols.

Toxicity — where the trade-off shows up

The two therapies have meaningfully different toxicity profiles:

Toxicity type	Lu-177 DOTATATE (Lutathera)	Ac-225 DOTATATE
Hematologic (any grade)	~80% mild-moderate	~80% mild-moderate (similar)
Hematologic (Grade 3-4)	~10% (NETTER-1: lymphopenia 9%, thrombocytopenia 2%, neutropenia 1%)	~15-20% (Ballal cohort)
Renal (Grade 3-4)	~1% with proper amino acid co-infusion	~5% (theoretically lower, but data still maturing)
Nausea/vomiting (any grade)	~60% (mostly from amino acid co-infusion)	~50%
Fatigue (any grade)	~40%	~50-60%
Xerostomia (significant)	Mild and rare	Common — but less than Ac-225 PSMA because DOTATATE has lower salivary gland uptake
MDS/leukaemia (long-term, 5+ years)	~1.5% cumulative (Bergsma, NETTER-1 long-term)	Data still maturing

The takeaway: hematologic and renal toxicity are broadly comparable between Lu-177 and Ac-225 DOTATATE in published cohorts, with the alpha-emitter showing modestly higher Grade 3-4 hematologic event rates in the largest Indian cohort^[6]. Importantly, salivary gland toxicity is far less prominent for Ac-225 DOTATATE than for Ac-225 PSMA, because DOTATATE (a somatostatin analogue) has lower salivary gland binding affinity than PSMA-617^[7]. For detailed PRRT side-effect framework see our sourced guide.

The salvage role of Ac-225 after Lu-177

The most clinically established role for alpha PRRT is salvage therapy after progression on Lu-177 DOTATATE. The Ballal et al. cohort specifically addressed this setting: 32 patients with metastatic NET who had progressed on Lu-177 DOTATATE were treated with Ac-225 DOTATATE. The disease control rate was 78.1 percent, with 15.7 percent showing partial response. Median progression-free survival was not reached at the time of publication^[6].

The Yadav et al. AIIMS cohort (n=23) showed similar findings, with 50 percent partial response rate in the salvage-after-Lu-177 setting^[8]. These data establish Ac-225 DOTATATE as a legitimate salvage option for patients who:

Have shown initial response to Lu-177 DOTATATE
Have later progressed on Lu-177
Still demonstrate SSTR2 expression on follow-up Ga-68 DOTATATE PET-CT (Krenning score ≥ 2)
Have adequate baseline kidney and marrow function for a second radionuclide therapy course

Clinical note · sequencing matters

Current evidence supports Lu-177 DOTATATE as first-line PRRT and Ac-225 DOTATATE as salvage. The reverse sequence (Ac-225 first, Lu-177 salvage) has not been systematically studied and is not standard practice. Investigational tandem Lu-177/Ac-225 approaches are being explored at experienced centres but remain unestablished^[9].

Patient selection — how the choice is actually made

The selection logic at experienced theranostics centres typically follows:

First-line metastatic well-differentiated NET — Lu-177 DOTATATE is the standard of care, based on the NETTER-1 phase III trial^[5]. Ac-225 is generally not used first-line outside investigational protocols.
Post-Lu-177 progression with maintained SSTR expression — Ac-225 DOTATATE salvage is a recognised option, supported by Ballal and Yadav cohort data^[6]^[8].
Bulky disease — Lu-177 favoured for its longer beta range and crossfire effect.
Bone marrow infiltration — Ac-225 theoretically favoured for shorter alpha range and reduced marrow crossfire, though direct comparative data are limited^[3].
Grade 3 NET / NEC — both Lu-177 and Ac-225 have been studied; response rates are lower than in Grade 1-2 NETs but meaningful for selected patients^[10].

For more on the broader PRRT framework including who is a candidate, see Is PRRT right for you?

Helsinki framing for Ac-225 PRRT

Ac-225 DOTATATE is not FDA-approved as a registered therapy. At FMRI it is delivered under the Helsinki Declaration framework with written informed consent that addresses: investigational status, the smaller published evidence base relative to Lu-177 DOTATATE, the post-Lu-177 salvage indication, hematologic and renal toxicity risks, and the patient's right to decline or withdraw at any point^[11].

The informed consent process mirrors the framework used for Ac-225 PSMA — a two-stage discussion that gives patients time to read the published data and return for second-visit written consent. Family-member participation is encouraged.

Cost, access, and practical realities

Practical access differences:

Lu-177 supply is comparatively stable — produced by reactor-irradiation of ytterbium-176, with multiple commercial suppliers globally. Lutathera (Novartis) is FDA- and EMA-approved with established commercial logistics^[12].
Ac-225 supply is constrained — currently produced primarily by three facilities globally (Oak Ridge, JRC Karlsruhe, Russia) from extracted thorium-229 stockpiles, with annual global supply of only approximately 1.7 GBq^[13]. Accelerator-produced Ac-225 (TRIUMF, Brookhaven National Laboratory, Argonne) is expected to expand supply meaningfully over 2025-2027^[14].
Cost per cycle — Ac-225 DOTATATE is substantially more expensive per cycle than Lu-177 DOTATATE because of the radionuclide cost and limited supply, though specific figures vary by institution and country.
Inpatient versus outpatient — both can be delivered as overnight inpatient stays at most experienced centres; some centres deliver Lu-177 as longer day-procedures.

The bottom line — choice in plain terms

Lu-177 DOTATATE is the standard-of-care first-line PRRT for metastatic well-differentiated SSTR-positive NET, supported by the largest evidence base including the NETTER-1 phase III trial and long-term cohort data^[5]^[15].
Ac-225 DOTATATE is investigational but with meaningful response signals (78 percent disease control rate) in patients who have progressed on Lu-177 with maintained SSTR expression — making it the most established salvage PRRT option^[6].
The choice is sequential, not competitive — Lu-177 first, Ac-225 as salvage. The reverse sequence is not standard practice.
Toxicity profiles are broadly comparable, with the trade-offs in physics translating into modestly different patterns of hematologic and renal effect.
Ac-225 DOTATATE delivery at FMRI is under Helsinki Declaration informed consent given the investigational status^[11].

Important

This article is general medical information for patient and clinician education. Treatment decisions for metastatic NET — including which PRRT to use, when to consider salvage, and how to integrate PRRT with other systemic therapies — should be made in a multidisciplinary review that includes nuclear medicine, medical oncology, and surgical oncology specialists familiar with your specific clinical context.

"When patients ask which is better — alpha or beta PRRT — the honest answer is that the question is framed wrong. The clinically meaningful framing is sequencing: Lu-177 first, with its larger evidence base and predictable toxicity profile; Ac-225 in the salvage line for patients who respond initially and later progress with maintained SSTR uptake. Picking the radionuclide is rarely the hardest decision — picking the right moment to switch is."

Dr. Ishita B. Sen, MD · Director & Chief, Nuclear Medicine, FMRI

Comparison consult · which radioligand fits your case

Whether Lu-177 DOTATATE or Ac-225 DOTATATE is right for your situation depends on prior treatments, current SSTR imaging, organ function, and disease distribution. FMRI's nuclear medicine team can review your specific case — including Ga-68 DOTATATE PET-CT, biochemistry, and prior PRRT history — to help determine which approach makes sense.

Discuss Lu-177 vs Ac-225 for your case · WhatsApp +91 8800 988936

For patients & referring clinicians

Frequently asked questions

Q01 What is the difference between alpha PRRT and beta PRRT?

Alpha PRRT uses an alpha-emitting radionuclide (Ac-225 currently) attached to a somatostatin analogue (DOTATATE); beta PRRT uses a beta-emitting radionuclide (Lu-177 standardly). The alpha particles travel only 50-100 micrometres but deposit ~500× more energy per micrometre than beta particles, which travel ~2.5 mm. The result: stronger localised tumour killing with alpha; broader crossfire effect with beta [1][2].

Q02 Which is better — alpha PRRT or beta PRRT?

Neither is universally better. Lu-177 DOTATATE (beta) is the established first-line standard with the largest evidence base, including the NETTER-1 phase III trial [5]. Ac-225 DOTATATE (alpha) has its strongest role as salvage therapy after Lu-177 progression, where it shows ~78% disease control rate [6]. The choice is sequential, not competitive — Lu-177 first, Ac-225 as salvage.

Q03 How well does Ac-225 DOTATATE work?

The largest published cohort (Ballal et al., AIIMS New Delhi) reported, in 91 treatment-naïve patients: 24% overall response rate (RECIST), 92.3% disease control rate, median PFS not reached. In 32 post-Lu-177 salvage patients: 15.7% ORR, 78.1% DCR, mPFS not reached [6]. The Yadav cohort (n=23) reported 50% partial response in salvage [8].

Q04 Is Ac-225 PRRT approved?

No. Ac-225 DOTATATE is investigational as of 2026 — not FDA-approved. Lu-177 DOTATATE (Lutathera) is the FDA-approved (2018) PRRT for SSTR-positive midgut NETs [16]. Ac-225 DOTATATE at experienced theranostics centres is delivered under Helsinki Declaration informed-consent frameworks [11].

Q05 Can I have Ac-225 PRRT first, before Lu-177?

Ac-225 PRRT as first-line treatment has not been systematically studied and is not standard practice. The established sequence is Lu-177 DOTATATE first, then Ac-225 DOTATATE as salvage if disease progresses with maintained SSTR2 expression [9]. Investigational tandem Lu-177/Ac-225 approaches are being explored but remain unestablished.

Q06 Why is xerostomia less of a problem with Ac-225 DOTATATE than Ac-225 PSMA?

DOTATATE binds the somatostatin receptor type 2 (SSTR2), which is expressed at very low density on salivary glands. PSMA-617 binds PSMA, which is expressed at meaningful density on salivary glands. The combination of high-LET alpha radiation with PSMA salivary uptake produces the prominent xerostomia of Ac-225 PSMA — a problem largely absent from Ac-225 DOTATATE [7].

Q07 What is the toxicity difference between Ac-225 and Lu-177 DOTATATE?

Hematologic toxicity is broadly comparable in any-grade events (~80% of patients on both); Grade 3-4 hematologic events are modestly more common with Ac-225 (~15-20%) than with Lu-177 (~10%) [5][6]. Renal toxicity is similar with proper amino acid protection. Long-term effects (MDS, leukaemia) are well-characterised for Lu-177 (~1.5% combined cumulative incidence) but data are still maturing for Ac-225 [17].

Q08 How is Ac-225 supply constrained?

Ac-225 is currently produced primarily by three reactor-based facilities globally (Oak Ridge, JRC Karlsruhe, Russia) from extracted thorium-229 stockpiles, with annual global supply of approximately 1.7 GBq [13]. Accelerator-produced Ac-225 from TRIUMF (Canada), Brookhaven National Laboratory, and Argonne is expected to expand supply over 2025-2027 [14]. Lu-177 supply is comparatively stable.

Q09 Can both Ac-225 and Lu-177 be combined?

Investigational tandem approaches combining both radionuclides in a single therapy course are being explored at a small number of centres, with limited but encouraging early data [9][18]. This is not standard practice and is currently delivered under research protocols rather than routine care. The rationale is to combine the alpha advantage in micrometastatic disease with the beta advantage in bulky lesions.

Q10 What does "high LET" mean and why does it matter?

LET stands for linear energy transfer — the energy deposited per micrometre of tissue. High-LET radiation (alpha particles, ~100 keV/µm) causes dense double-strand DNA breaks that cancer cells struggle to repair. Low-LET radiation (beta particles, ~0.2 keV/µm) causes mostly single-strand breaks that cells can repair more readily. The high-LET nature of alpha radiation theoretically explains why Ac-225 can produce responses in tumours resistant to Lu-177 [4].

Q11 Where is Ac-225 DOTATATE available in India?

A small number of Indian tertiary centres with active nuclear medicine theranostics programmes offer Ac-225 DOTATATE under Helsinki-framework consent, including AIIMS New Delhi, FMRI Gurugram, and others. The Indian published experience is substantial — the Ballal et al. AIIMS cohort is one of the largest globally [6]. Delivery requires Ga-68 DOTATATE PET-CT for eligibility, biochemical workup, multidisciplinary review, and signed Helsinki-framework consent.

Q12 Will accelerator-produced Ac-225 change access?

Yes, plausibly. The TRIUMF accelerator-produced Ac-225 programme at Vancouver, the Brookhaven National Laboratory programme, and the Argonne programme are projected to expand global Ac-225 supply meaningfully over 2025-2027 [14]. Higher supply should reduce per-cycle cost and broaden clinical availability, including the feasibility of larger randomised trials comparing Ac-225 PRRT against Lu-177 PRRT head-to-head.

Citations & references

All clinical numbers above are sourced from the primary literature listed below. Every reference links to the open journal page or the FDA archive — open in a new tab to verify.

[1] McDevitt MR, Sgouros G, Sofou S. Targeted and Nontargeted α-Particle Therapies. Annu Rev Biomed Eng. 2018;20:73-93. View source ↗

[2] Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19(9):589-608. View source ↗

[3] Morgenstern A, Apostolidis C, Bruchertseifer F. Supply and Clinical Application of Actinium-225 and Bismuth-213. Semin Nucl Med. 2020;50(2):119-123. View source ↗

[4] Pouget JP, Constanzo J. Revisiting the Radiobiology of Targeted Alpha Therapy. Front Med (Lausanne). 2021;8:692436. View source ↗

[5] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1). N Engl J Med. 2017;376(2):125-135. View source ↗

[6] Ballal S, Yadav MP, Bal C, et al. Concomitant ¹⁷⁷Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumors and updated outcomes of ²²⁵Ac-DOTATATE therapy in 91 patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):934-946. View source ↗

[7] Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues. Eur J Nucl Med. 2001;28(7):836-846. View source ↗

[8] Yadav MP, Ballal S, Sahoo RK, et al. Efficacy and safety of ²²⁵Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study. Eur J Nucl Med Mol Imaging. 2022;49(5):1595-1606. View source ↗

[9] Khreish F, Ebert N, Ries M, et al. ²²⁵Ac-PSMA-617/¹⁷⁷Lu-PSMA-617 tandem therapy of metastatic CRPC: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47(3):721-728. View source ↗

[10] Carlsen EA, Fazio N, Granberg D, et al. Peptide receptor radionuclide therapy in metastatic neuroendocrine carcinoma. Endocr Relat Cancer. 2019;26(2):227-239. View source ↗

[11] World Medical Association. Declaration of Helsinki — Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191-2194. View source ↗

[12] U.S. Food and Drug Administration. LUTATHERA (lutetium Lu 177 dotatate) prescribing information. View source ↗

[13] Boll RA, Malkemus D, Mirzadeh S. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Radiat Isot. 2005;62(5):667-679. View source ↗

[14] Robertson AKH, Ramogida CF, Schaffer P, Radchenko V. Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences. Curr Radiopharm. 2018;11(3):156-172. View source ↗

[15] Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-Term Efficacy, Survival, and Safety of [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate. Clin Cancer Res. 2017;23(16):4617-4624. View source ↗

[16] U.S. Food and Drug Administration. LUTATHERA prescribing information (2018 initial approval). View source ↗

[17] Bergsma H, van Lom K, Raaijmakers MHGP, et al. Persistent Hematologic Dysfunction After PRRT with ¹⁷⁷Lu-DOTATATE. J Nucl Med. 2018;59(3):452-458. View source ↗

[18] Rosar F, Hau F, Bartholomä M, et al. Molecular imaging and biochemical response assessment after a single cycle of [²²⁵Ac]Ac-PSMA-617/[¹⁷⁷Lu]Lu-PSMA-617 tandem therapy. Theranostics. 2021;11(9):4050-4060. View source ↗

[19] Strosberg JR, Caplin ME, Kunz PL, et al. ¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety. Lancet Oncol. 2021;22(12):1752-1763. View source ↗

[20] Strosberg JR, Caplin ME, Kunz PL, et al. NETTER-1 long-term overall survival update. Lancet Oncol. 2021;22(12):1752-1763. View source ↗

[21] Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2015;42(1):5-19. View source ↗

[22] Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS Consensus Guidelines for PRRT in Neuroendocrine Neoplasms. Neuroendocrinology. 2017;105(3):295-309. View source ↗

[23] Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. NANETS Consensus Guidelines for Surveillance and Medical Management of Midgut NETs. Pancreas. 2017;46(6):707-714. View source ↗

[24] Pavel M, Öberg K, Falconi M, et al. ESMO Clinical Practice Guidelines for GEP-NEN. Ann Oncol. 2020;31(7):844-860. View source ↗

[25] Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30(1):9-15. View source ↗

[26] Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on PRRNT in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800-816. View source ↗

[27] Sansovini M, Severi S, Ianniello A, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with ¹⁷⁷Lu-DOTATATE. Eur J Nucl Med Mol Imaging. 2017;44(3):490-499. View source ↗

[28] Severi S, Sansovini M, Ianniello A, et al. Feasibility and utility of re-treatment with ¹⁷⁷Lu-DOTATATE in GEP-NENs. Eur J Nucl Med Mol Imaging. 2015;42(13):1955-1963. View source ↗

[29] Eychenne R, Chérel M, Haddad F, et al. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy. Pharmaceutics. 2021;13(6):906. View source ↗

[30] Strosberg JR, Caplin ME, Kunz PL, et al. NETTER-2 trial. Lancet. 2024;403(10446):2807-2817. View source ↗

[31] Pryma DA, Chin BB, Noto RB, et al. Efficacy and Safety of High-Specific-Activity ¹³¹I-MIBG Therapy. J Nucl Med. 2019;60(5):623-630. View source ↗

[32] Hofman MS, Lawrentschuk N, Francis RJ, et al. PSMA PET-CT accuracy in metastatic disease. Lancet. 2020;395(10231):1208-1216. View source ↗

About the Author

Dr. Ishita B. Sen

MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York

Director and Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited (TPPL). Two decades of clinical practice in PSMA imaging and PSMA-directed radioligand therapy, with one of the largest Indian institutional experiences in Lu-PSMA.

Full profile → All publications Book a consult